asenapine

Also Known As:

5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz(2,3-6,7)oxepino(4,5-c)pyrrole; ORG 5222; ORG-5222; Saphris; Secuado; asenapine maleate; trans-5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz(2,3:6,7)oxepino(4,5-c)pyrrole

Networked: 262 relevant articles (53 outcomes, 78 trials/studies)

Relationship Network

Drug Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Polycyclic Aromatic Hydrocarbons: 2020
        Benzocycloheptenes
        Dibenzocycloheptenes
        asenapine: 262
Polycyclic Compounds: 6
- Polycyclic Aromatic Hydrocarbons: 2020
  - Benzocycloheptenes
    - Dibenzocycloheptenes
      - asenapine: 262

Experts

1.	Mackle, Mary: 16 articles (01/2018 - 03/2011)
2.	Zhao, Jun: 16 articles (06/2015 - 11/2009)
3.	Shahid, Mohammed: 14 articles (03/2012 - 02/2008)
4.	McIntyre, Roger S: 12 articles (12/2021 - 11/2009)
5.	Szegedi, Armin: 12 articles (01/2018 - 03/2011)
6.	Panagides, John: 12 articles (05/2012 - 01/2007)
7.	Citrome, Leslie: 10 articles (01/2022 - 01/2011)
8.	Alphs, Larry: 8 articles (11/2013 - 01/2007)
9.	Findling, Robert L: 7 articles (09/2019 - 06/2015)
10.	Mathews, Maju: 7 articles (01/2018 - 06/2015)

Related Diseases

1.	Schizophrenia (Dementia Praecox) 11/05/2023 - "Optimal dose for the efficacy of asenapine in patients with schizophrenia: Real-world data." 05/01/2012 - "The efficacy of asenapine was reported in 3 clinical studies in patients with schizophrenia, 1 each in acute and long-term settings, measured as significant changes in Positive and Negative Syndrome Scale scores over 6 and 52 weeks. " 09/01/2009 - "In two randomized, controlled trials in adult patients with acute schizophrenia, treatment with asenapine reduced from baseline the clinician-assessed Positive and Negative Syndrome Scale (PANSS) total score to a significantly greater extent than placebo at 6 weeks. " 01/01/2020 - "Early improvement in negative symptoms, poor attention and impulse control, and lack of insight, in particular predicted subsequent treatment response in patients with schizophrenia during treatment with asenapine as accurately as prediction based on overall symptom severity." 12/01/2012 - "These meta-analyses indicate that the efficacy of asenapine for acute schizophrenia is superior to placebo and comparable to several other SGAs."
2.	Mania (Manias) 05/01/2012 - "In addition, efficacy of asenapine was reported in 2 studies in acute mania as well as extension phases of both 9 and 40 weeks, as determined by significant changes in Young Mania Rating Scale scores. " 03/01/2011 - "In two large (both n = 480), well designed, 3-week trials in adult patients with bipolar I disorder, asenapine monotherapy was significantly more effective than placebo at improving mania symptoms, as assessed using the Young Mania Rating Scale total score (YMRS; primary endpoint), with significant differences between the asenapine and placebo groups occurring after 2 days of treatment. " 02/01/2012 - "Adjunctive asenapine significantly improved mania versus placebo at week 3 (primary end point) and weeks 2 to 12. " 04/01/2013 - "Evidence from real-world case reports demonstrates that - as in clinical trials - asenapine is effective in treating mania and mixed episodes associated with bipolar I disorder, whether used as monotherapy or in combination with a mood stabiliser. " 02/15/2013 - "These exploratory analyses provide supportive evidence for the efficacy of asenapine in treating the associated symptoms of mania and depression in bipolar I patients with mixed episodes."
3.	Bipolar Disorder (Manic Depressive Psychosis) 01/01/2011 - "The objective is to review the efficacy of asenapine in bipolar disorder, with a particular focus on acceptability and adherence to treatment. " 05/01/2010 - "Pharmacology and efficacy of asenapine for manic and mixed states in adults with bipolar disorder." 01/15/2016 - "Phase IIIb, international, double-blind, fixed-dose, parallel-group, 3-week placebo-controlled trial of asenapine 5 and 10mg bid in adults with an acute bipolar I disorder manic or mixed episode. " 09/01/2013 - "The aim of this study was to quantitatively review, using a meta-analytic approach, randomized-controlled trials analyzing the efficacy and safety profiles of asenapine in the treatment of bipolar disorder (BD). " 06/20/2011 - "Controlled studies of asenapine in patients with acute bipolar depression are necessary to confirm the generalizability of these findings."
4.	Psychotic Disorders (Schizoaffective Disorder) 01/01/2017 - "Asenapine for the Treatment of Psychotic Disorders." 12/01/2015 - "The authors present a case of suspected pseudo-Stauffer's syndrome in a male with treatment refractory schizoaffective disorder following asenapine use. " 01/01/2015 - "[Clinical experience and perspectives of using asenapine in stopping acute endogenous psychosis]." 05/01/2012 - "Short-term safety and pharmacokinetic profile of asenapine in older patients with psychosis." 01/01/2012 - "The pharmacodynamic profile of asenapine provides a rationale for hypothesizing efficacy in the treatment of cognitive deficits in mood and psychotic disorders. "
5.	Substance-Related Disorders (Drug Abuse) 02/01/2017 - "Does the efficacy of asenapine in bipolar disorder increase in the presence of comorbidity with a substance use disorder? " 04/01/2014 - "Other papers suggested that asenapine and olanzapine were efficacious for mixed episodes, with olanzapine being equally effective in patients with or without substance abuse. " 01/01/2019 - "We report a 38-years-old man with substance use disorders in methadone maintenance treatment who relapsed on cocaine use and presented CIPD that was satisfactorily treated with asenapine. "

Related Drugs and Biologics

1.	Olanzapine (Zyprexa)
2.	Antipsychotic Agents (Antipsychotics)
3.	Risperidone (Risperdal Consta)
4.	Aripiprazole (Abilify)
5.	Haloperidol (Haldol)
6.	ziprasidone (Geodon)
7.	Clozapine (Clozaril)
8.	Dopamine (Intropin)
9.	Quetiapine Fumarate (Seroquel)
10.	Paliperidone Palmitate

Related Therapies and Procedures

1.	Therapeutics
2.	Secondary Prevention
3.	Patient Readmission
4.	Length of Stay
5.	Aftercare (After-Treatment)